만성적 비특이적인 어지럼 환자에서 Prostaglandin I2의 경구 투약 효과 (Efficacy of Oral Prostaglandin I2 in Patients with Chronic Nonspecific Vertigo)

서지정보

· 발행기관 : 대한평형의학회
· 수록지 정보 : Research in Vestibular Science / 10권 / 4호 / 115 ~ 120페이지
· 저자명 : 임현우, 김지원, 정종우, 안윤숙, 최승효, 박홍주

초록

Background and Objectives: The aim of this study is to evaluate the efficacy of prostaglandin I2 (PGI2) in the patients with chronic nonspecific vertigo using questionnaires of dizziness handicap inventory (DHI) and vertigo symptom scale (VSS). Materials and Methods: Forty two patients with chronic nonspecific vertigo from May to December 2010 were enrolled in this study. We administered Berast (synthetic PGI2, beraprost sodium) 2 tablets (0.04 mg) twice a day to patients. Before and after 2, 4 weeks the end of administration patients underwent DHI and VSS for evaluation of state of the vertigo. Results: Twenty four of 42 patients completed this clinical trial. Mean DHI scale score decreased significantly from 23.00 (±21.75) to 17.75 (±19.78) (p=0.004). All DHI subscales, physical, functional, and emotional factors, decreased after treatment of prostaglandin I2. VSS scale also showed significant decrease from 3.63 (±2.55) to 2.50 (±2.95) (p=0.044). Conclusion:Prostaglandin I2 may be one of the treatments to improve symptoms in the patient s with chronic nonspecific vertigo.

영어초록

Background and Objectives: The aim of this study is to evaluate the efficacy of prostaglandin I2 (PGI2) in the patients with chronic nonspecific vertigo using questionnaires of dizziness handicap inventory (DHI) and vertigo symptom scale (VSS). Materials and Methods: Forty two patients with chronic nonspecific vertigo from May to December 2010 were enrolled in this study. We administered Berast (synthetic PGI2, beraprost sodium) 2 tablets (0.04 mg) twice a day to patients. Before and after 2, 4 weeks the end of administration patients underwent DHI and VSS for evaluation of state of the vertigo. Results: Twenty four of 42 patients completed this clinical trial. Mean DHI scale score decreased significantly from 23.00 (±21.75) to 17.75 (±19.78) (p=0.004). All DHI subscales, physical, functional, and emotional factors, decreased after treatment of prostaglandin I2. VSS scale also showed significant decrease from 3.63 (±2.55) to 2.50 (±2.95) (p=0.044). Conclusion:Prostaglandin I2 may be one of the treatments to improve symptoms in the patient s with chronic nonspecific vertigo.

참고자료

· 없음